Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues

Key Takeaways FOLD reported Q4 EPS of 10 cents, missing estimates, as revenues rose 24% Y/Y to $185.2M.Amicus saw Galafold sales rise 14% and Pombiliti plus Opfolda jump 51% Y/Y at constant exchange rates.BioMarin will acquire Amicus for $14.50 per share in a $4.8B cash deal set to close in Q2 2026.Amicus Therapeutics (FOLD) reported adjusted earnings of 10 cents per share for the fourth quarter of 2025, which missed the Zacks Consensus Estimate of 13 cents. The company had reported adjusted earnings of 9 c ...